Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain
In AT-naïve and AT-experienced patients, etrasimod is a dominant therapy (cost savings, greater effectiveness) compared with commonly used ATs.
Authors
- Alfonso De Lossada Juste
- Alberto de la Cuadra-Grande (ORCID: https://orcid.org/0000-0002-2501-3049)
- Emilio Monte‐Boquet (ORCID: https://orcid.org/0000-0001-5352-2601)
- Ana Cábez (ORCID: https://orcid.org/0000-0003-0808-8855)
- Alfredo José Lucendo (ORCID: https://orcid.org/0000-0003-1183-1072)
- Itziar Oyagüez (ORCID: https://orcid.org/0000-0002-3047-6152)
- Iago Rodríguez–Lago (ORCID: https://orcid.org/0000-0003-1133-4578)
- Fernándo Muñoz (ORCID: https://orcid.org/0000-0003-1295-7240)
Institutions
- Universidad de Salamanca (ES)
- Saint Louis University (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital General de Tomelloso (ES)
- Hospital de Galdakao (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Pfizer (Spain) (ES)
- Pharmacoeconomics and Health Outcomes Research Iberia (Spain) (ES)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-11-16
- DOI
- https://doi.org/10.1007/s41669-025-00619-6
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- CSL Behring
- Baxalta
- Eisai
- Astellas Pharma
- Tillotts Pharma
- Ipsen
- LEO Pharma